Then, in 55 AML patients with NPM1 mutations, the MFC MRD status after the second consolidation exerted a significant prognostic impact on both RFS (median RFS, 32 vs 10 months, P = 0.036) and OS (median OS, NR vs 19 months, P = 0.028) (Figures 5A, B). This evidence concerns the gene NPM1 and acute myeloid leukemia.